Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial
CPX-351 (Europe: Vyxeos ® liposomal; United States: Vyxeos®) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. In a phase 3 study in older adults with newly di... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 26, 2022 Category: Hematology Authors: Jorge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet and Thomas Prebet Tags: Brief Report Source Type: research
Drugging KRAS: current perspectives and state-of-art review
After decades of efforts, we have recently made progress into targeting KRAS mutations in several malignancies. Known as the ‘holy grail’ of targeted cancer therapies, KRAS is the most frequently mutated oncog... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 25, 2022 Category: Hematology Authors: Kaushal Parikh, Giuseppe Banna, Stephen V. Liu, Alex Friedlaender, Aakash Desai, Vivek Subbiah and Alfredo Addeo Tags: Review Source Type: research
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
Immunotherapy for cancer is a rapidly developing treatment that modifies the immune system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 family that plays an immunoregulatory ro... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 25, 2022 Category: Hematology Authors: Binghao Zhao, Huanzhang Li, Yu Xia, Yaning Wang, Yuekun Wang, Yixin Shi, Hao Xing, Tian Qu, Yu Wang and Wenbin Ma Tags: Review Source Type: research
Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry
In this study, we attempted to identify PDAC T cell epitopes by mass spectrometry... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 25, 2022 Category: Hematology Authors: Kenji Fujiwara, Yingkuan Shao, Nan Niu, Tengyi Zhang, Brian Herbst, Mackenzie Henderson, Stephen Muth, Pingbo Zhang and Lei Zheng Tags: Correspondence Source Type: research
Correction: Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets
(Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 24, 2022 Category: Hematology Authors: Rui Qin, Feng ‑Ming You, Qian Zhao, Xin Xie, Cheng Peng, Gu Zhan and Bo Han Tags: Correction Source Type: research
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Extramedullary multiple myeloma (EMD) is an aggressive subentity of multiple myeloma (MM) with poor prognosis. As more innovative therapeutic approaches are needed for the treatment of MM with EMD, we conducte... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 23, 2022 Category: Hematology Authors: Ja Min Byun, Chang-Ki Min, Kihyun Kim, Soo-Mee Bang, Je-Jung Lee, Jin Seok Kim, Sung-Soo Yoon and Youngil Koh Tags: Research Source Type: research
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
We report here the results of t... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 21, 2022 Category: Hematology Authors: Maud Toulmonde, Sophie Cousin, Mich èle Kind, Jean-Philippe Guegan, Alban Bessede, Francois Le Loarer, Raul Perret, Coralie Cantarel, Carine Bellera and Antoine Italiano Tags: Correspondence Source Type: research
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) has become curable over 95% patients under a complete chemo-free treatment with all-trans retinoic acid (ATRA) and arsenic trioxide in low-risk patients. Minimizing chemother... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 18, 2022 Category: Hematology Authors: Ya-Fang Ma, Ying Lu, Qian Wu, Yin-Jun Lou, Min Yang, Jie-Yu Xu, Cai-Hong Sun, Li-Ping Mao, Gai-Xiang Xu, Li Li, Jian Huang, Huai-Yu Wang, Li-Jiang Lou, Hai-Tao Meng, Jie-Jing Qian, Wen-Juan Yu & hellip; Tags: Correspondence Source Type: research
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and maintaining genome stabi... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 17, 2022 Category: Hematology Authors: Shuangying Li, Liangliang Wang, Yuanyuan Wang, Changyi Zhang, Zhenya Hong and Zhiqiang Han Tags: Review Source Type: research
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair
DNA lesions induced by alkylating agents are repaired by two canonical mechanisms, base excision repair dependent on poly(ADP) ribose polymerase 1 (PARP1) and the other mediated by O6-methylguanine (O6meG)-DNA m... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 14, 2022 Category: Hematology Authors: Jodie D. Cropper, Dauren S. Alimbetov, Kevin T. G. Brown, Rostislav I. Likhotvorik, Andrew J. Robles, James T. Guerra, Boxue He, Yidong Chen, Youngho Kwon and Raushan T. Kurmasheva Tags: Correspondence Source Type: research
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
Metastatic prostate cancer (PC) is a leading cause of cancer death in men worldwide. Targeting of the culprits of disease progression is an unmet need. Interleukin (IL)-30 promotes PC onset and development, bu... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 13, 2022 Category: Hematology Authors: Carlo Sorrentino, Luigi D ’Antonio, Stefania Livia Ciummo, Cristiano Fieni, Lorena Landuzzi, Francesca Ruzzi, Simone Vespa, Paola Lanuti, Lavinia Vittoria Lotti, Pier Luigi Lollini and Emma Di Carlo Tags: Research Source Type: research
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
We assessed the mechanism by which multiple myeloma (MM) shapes the bone marrow (BM) microenvironment and affects M Φ polarization. (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 10, 2022 Category: Hematology Authors: Katia Beider, Valeria Voevoda-Dimenshtein, Ali Zoabi, Evgenia Rosenberg, Hila Magen, Olga Ostrovsky, Avichai Shimoni, Lola Weiss, Michal Abraham, Amnon Peled and Arnon Nagler Tags: Research Source Type: research
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
The United States Food and Drug Administration (US FDA) has always been a forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs (excluding vaccines, cell-based therapies, and gene t... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 8, 2022 Category: Hematology Authors: Qing Wu, Wei Qian, Xiaoli Sun and Shaojie Jiang Tags: Review Source Type: research
The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy
Pediatric cancers are the driving cause of death for children and adolescents. Due to safety requirements and considerations, treatment strategies and drugs for pediatric cancers have been so far scarcely stud... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 8, 2022 Category: Hematology Authors: Hua Wang, Xiaowen Zhou, Chenbei Li, Shuxiang Yan, Chengyao Feng, Jieyu He, Zhihong Li and Chao Tu Tags: Review Source Type: research
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma
Besides featured glucose consumption, recent studies reveal that cancer cells might prefer “addicting” specific energy substrates from the tumor microenvironment (TME); however, the underlying mechanisms remai... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - October 8, 2022 Category: Hematology Authors: Tongyan Liu, Chencheng Han, Panqi Fang, Zhifei Ma, Xiaoxiao Wang, Hao Chen, Siwei Wang, Fanchen Meng, Cheng Wang, Erbao Zhang, Guozhang Dong, Hongyu Zhu, Wenda Yin, Jie Wang, Xianglin Zuo, Mantang Qiu & hellip; Tags: Research Source Type: research
